- Mortality Risk in Diabetic Heart Attack Patients
Mortality Risk in Diabetic Heart Attack Patients
In a study that included nearly 60,000 patients with a first-time heart attack, patients with diabetes who received conventional platelet-inhibition with clopidogrel had a lower reduction in the risk of all-cause death and cardiovascular death compared with heart attack patients without diabetes who received clopidogrel, according to a study in the September 5 issue of JAMA. 1
“Patients with diabetes have an increased risk of ischemic adverse events and death compared with patients without diabetes,” according to background information in the article.
“Pharmacodynamic studies have shown that persistently high platelet reactivity is common in patients with diabetes in spite of clopidogrel treatment. Clinical trials have not convincingly demonstrated that clopidogrel benefits patients with diabetes as much patients without diabetes.”
Charlotte Andersson, M.D., Ph.D., of Gentofte Hospital, Hellerup, Denmark, and colleagues analyzed the outcomes associated with clopidogrel treatment after heart attack in patients with and without diabetes.
The study included data from the Danish nationwide administrative registries between 2002-2009 of patients who were hospitalized with incident heart attack and who had survived and not undergone coronary artery bypass surgery 30 days after discharge and who were followed up for as long as 1 year. Analysis was conducted to investigate the association between clopidogrel treatment in patients with and without diabetes and the outcomes of all-cause mortality, cardiovascular mortality, and a composite end point of recurrent heart attack and all-cause mortality.
Of the 58,851 patients—7,247 of whom (12 percent) had diabetes—who were included in the analyses, 35,380 (60 percent) received clopidogrel at the beginning of the study. Patients were followed up for a median (midpoint) of 365 days. In total, 1,790 patients (25 percent) with and 7,931 patients (15 percent) without diabetes met the composite end point.
Of these, 1,225 (17 percent) with and 5,377 (10 percent) without diabetes died. Of the patients who died, 978 patients (80 percent) with and 4,100 patients (76 percent) without diabetes died of cardiovascular-related events.
Of patients with diabetes, those who took clopidogrel had lower crude incidence rates of all-cause mortality than those who were not taking clopidogrel. Of patients who did not have diabetes, those who took clopidogrel had lower crude incidence rates of all-cause mortality than those who did not take clopidogrel.
Adjusted for other variables, patients with diabetes were found to have a smaller relative risk reduction for mortality than patients without diabetes. “When adjusted, this finding applied for the all-cause mortality end point and the cardiovascular mortality end point, but not for the composite end point,” the authors write.
“In the present analysis, clopidogrel treatment was associated with a relative risk reduction of 25 percent for all-cause mortality, 23 percent for cardiovascular mortality, and 9 percent for the combination of recurrent myocardial infarction [MI; heart attack] and all-cause mortality in patients without diabetes, and a relative risk reduction of 11 percent for all-cause mortality but no significant reduction in cardiovascular mortality or the combined end point in patients with diabetes.”
“In summary, data from previous clinical trials and data from the present analyses strongly suggest that patients with diabetes have a significantly diminished relative effectiveness of conventional platelet-inhibition with clopidogrel after MI compared with patients without diabetes.
It should however be emphasized that considering the relatively higher absolute risks found for patients with diabetes, use of clopidogrel may still translate into a significant reduction in event rates for patients with diabetes, which data from the subgroup analyses supported. Available data nevertheless raise a possibility that patients with diabetes may benefit from a more potent platelet inhibitor strategy to achieve a relative risk reduction similar to patients without diabetes,” the researchers conclude.
Deepak L. Bhatt, M.D., M.P.H., of the VA Boston Healthcare System, Brigham and Women’s Hospital, and Harvard Medical School, Boston, writes in an accompanying editorial that the “study by Andersson et al highlights the elevated risk of recurrent myocardial infarction and cardiovascular mortality among patients with diabetes following MI.”2
“More needs to be done to reduce these risks among such patients. At least a portion of this excess risk appears due to platelet activity and function and to the effects of antiplatelet medications in patients with diabetes. Therefore, in appropriately selected patients, intensification of the antiplatelet regimen may be one method by which their outcomes might be markedly improved.”
1. (JAMA. 2012;308:882-889.
2. (JAMA. 2012;308:921-922.
DISCLAIMER: Bankix Systems Ltd is the registered name of a Canadian firm since 2003, and bankixsystems.com is its OFFICIAL website. Besides these entities, we have no relationship with anyone, business, website, or any other entity anywhere in the world, claiming to be Bankix Systems, or using a similar name, and creating the impression that it has some connection with our company. We do not endorse and are therefore, not responsible for any act or lack thereof by any such entity. Bankix Systems Ltd is also not responsible for the content of the description of products and services linked to our site nor does it necessarily endorse them. The information here provided is not for diagnosing/treating your health concerns. Kindly contact your doctor or health care professional for all your healthcare requirements.
Contents © 2003-2018, BankixSystems.com. All rights reserved. Unauthorized reproduction strictly prohibited. Information based on best available resources. Opinions are current and subject to change.